Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review

被引：24

作者：

Donnez, Jacques ^{[1
,2
]}

Courtoy, Guillaume E. ^{[3
]}

Donnez, Olivier ^{[4
]}

Dolmans, Marie-Madeleine ^{[3
,5
]}

机构：

[1] Catholic Univ Louvain, Ave Grandchamp 143, B-1150 Brussels, Belgium

[2] Catholic Univ Louvain, SRI, Ave Grandchamp 143, B-1150 Brussels, Belgium

[3] Catholic Univ Louvain, IREC, Pole Rech Gynecol, Ave Mounier 52-B1-52-02, B-1200 Brussels, Belgium

[4] Grp ELSAN, Polyclin Urbain 5, Inst Sein & Chirurg Gynecol Avignon ICA, Chemin Pont Deux Eaux 95, F-84000 Avignon, France

[5] Clin Univ St Luc, Gynecol Dept, Brussels, Belgium

来源：

REPRODUCTIVE BIOMEDICINE ONLINE | 2018年 / 37卷 / 02期

关键词：

PROGESTERONE-RECEPTOR MODULATORS; HORMONE AGONIST; MECHANISMS; SAFETY;

D O I：

10.1016/j.rbmo.2018.04.040

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life. The present review aims to provide insights into UPA indications and its mechanism of action. (C) 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

引用

页码：216 / 223

页数：8

共 46 条

[1] Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding [J].

Arendas, Kristina ;

Leyland, Nicholas A. .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2016, 38 (01) :80-83

[2]

Bayer, 2018, MIR SUMM PROD CHAR

[3] Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study [J].

Bernard, N. ;

Elefant, E. ;

Carlier, P. ;

Tebacher, M. ;

Barjhoux, C. E. ;

Bos-Thompson, M. A. ;

Amar, E. ;

Descotes, J. ;

Vial, T. .

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2013, 120 (05) :568-575

[4] The potential of selective progesterone receptor modulators for the treatment of uterine fibroids [J].

Bestel, Elke ;

Donnez, Jacques .

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (01) :79-92

[5] The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids [J].

Bouchard, Philippe ;

Chabbert-Buffet, Nathalie .

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 40 :105-110

[6] Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology [J].

Bouchard, Philippe .

GYNECOLOGICAL ENDOCRINOLOGY, 2014, 30 (10) :683-684

[7] Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications [J].

Chabbert-Buffet, N ;

Meduri, G ;

Bouchard, P ;

Spitz, IM .

HUMAN REPRODUCTION UPDATE, 2005, 11 (03) :293-307

[8] Fibroid growth and medical options for treatment [J].

Chabbert-Buffet, Nathalie ;

Esber, Nathalie ;

Bouchard, Philippe .

FERTILITY AND STERILITY, 2014, 102 (03) :630-639

[9]

Courtoy G. E., 2017, GYNECOL OBSTET INVES

[10]

Courtoy G. E., 2018, J CLIN ENDOCRINOL ME

← 1 2 3 4 5 →